498
Views
88
CrossRef citations to date
0
Altmetric
Review

Olfactory dysfunction as a diagnostic marker for Parkinson’s disease

, &
Pages 1773-1779 | Published online: 09 Jan 2014

References

  • Ansari KA, Johnson A. Olfactory function in patients with Parkinson’s disease. J. Chron. Dis.28, 493–497 (1975).
  • Ward CD, Hess WA, Calne DB. Olfactory impairment in Parkinson’s disease. Neurology33, 943–946 (1983).
  • Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry62, 436–446 (1997).
  • Doty RL, Deems D, Steller S. Olfactory dysfunction in Parkinson’s disease: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology38, 1237–1244 (1988).
  • Haehner A, Boesveldt S, Berendse HW et al. Prevalence of smell loss in Parkinson’s disease – a multicenter study. Parkinsonism Relat. Disord.15, 490–494 (2009).
  • Murphy C, Schubert CR, Cruickshanks KJ et al. Prevalence of olfactory impairment in older adults. JAMA288, 2307–2301 (2002).
  • Stern MB, Doty RL, Dotti M et al. Olfactory function in Parkinson’s disease subtypes. Neurology44, 266–268 (1994).
  • Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov. Disord.17, 867–876 (2002).
  • Hummel T. Olfactory evoked potentials as a tool to measure progression of Parkinson’s disease. In: Focus on Medicine – Vol. 14: New Developments in the Drug Therapy of Parkinson’s Disease. Chase T, Bedard P (Eds). Blackwell Science, Oxford, UK, 47–53 (1999).
  • Tissingh G, Berendse HW, Bergmans P et al. Loss of olfaction in de novo and treated Parkinson’s disease: possible implications for early diagnosis. Mov. Disord.16, 41–46 (2001).
  • Muller A, Mungersdorf M, Reichmann H, Strehle G, Hummel T. Olfactory function in Parkinsonian syndromes. J. Clin. Neurosci.9, 521–524 (2002).
  • Bohnen NI, Studenski SA, Constantine GM, Moore RY. Diagnostic performance of clinical motor and non-motor tests of Parkinson’s disease: a matched case–control study. Eur. J. Neurol.15(7), 685–691 (2008).
  • Hawkes CH, Shephard BC. Selective anosmia in Parkinson’s disease. Lancet341(8842), 435–436 (1993).
  • Daum RF, Sekinger B, Kobal G, Lang CJG. Riechprüfung mit ‘sniffin’ sticks’ zur klinischen Diagnostik des Morbus Parkinson. Nervenarzt71, 643–650 (2000).
  • Double KL, Rowe DB, Hayes M et al. Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch. Neurol.60(4), 545–549 (2003).
  • Bohnen NI, Gedela S, Kuwabara H et al. Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson’s disease J. Neurol.254(1), 84–90 (2007).
  • Witt M, Bormann K, Gudziol V et al. Biopsies of olfactory epithelium in patients with Parkinson’s disease. Mov. Disord.24(6), 906–914 (2009).
  • Müller A, Abolmaali ND, Hakimi AR et al. Olfactory bulb volumes in patients with Idiopathic Parkinson’s Disease – a pilot study. J. Neural Transm.112(10), 1363–1370 (2005).
  • Huisman E, Uylings HB, Hoogland PV. A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson’s disease. Mov. Disord.19, 687–692 (2004).
  • Winner B, Geyer M, Couillard-Despres S et al. Striatal deafferentation increases dopaminergic neurogenesis in the adult olfactory bulb. Exp Neurol.197, 113–121 (2006).
  • Scherfler C, Schocke MF, Seppi K et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson’s disease. Brain129(Pt 2), 538–542 (2005).
  • Westermann B, Wattendorf E, Schwerdtfeger U et al. Functional modulation of cortical olfactory pathways in Parkinson’s disease: an fMRI study. J. Neurol. Neurosurg. Psychiatry79, 19–24 (2008).
  • Silveira-Moriyama L, Holton JL, Kingsbury A et al. Regional differences in the severity of Lewy body pathology across the olfactory cortex. Neurosci. Lett.453(2), 77–80 (2009).
  • Davidson TM, Freed C, Healy MP, Murphy C. Rapid clinical evaluation of anosmia in children: the alcohol sniff test. Ann. NY Acad. Sci.855, 787–792 (1998).
  • Hummel T, Konnerth CG, Rosenheim K, Kobal G. Screening of olfactory function with a four-minute odor identification test: reliability, normative data, and investigations in patients with olfactory loss. Ann. Otol. Rhinol. Laryngol.110, 976–981 (2001).
  • Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. “Sniffin’ Sticks”: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem. Senses22, 39–52 (1997).
  • Kondo H, Matsuda T, Hashiba M, Baba S. A study of the relationship between the T&T olfactometer and the University of Pennsylvania smell identification test in a Japanese population. Am. J. Rhinol.12, 353–358 (1998).
  • Larsson M, Nilsson LG, Olofsson JK, Nordin S. Demographic and cognitive predictors of cued odor identification: evidence from a population-based study. Chem. Senses29, 547–554 (2004).
  • Ehrenstein WH, Ehrenstein A. Psychophysical methods. In: Modern Techniques in Neuroscience Research. Windhorst U, Johansson H (Eds). Springer, Berlin, Germany, 1211–1241 (1999).
  • Lotsch J, Lange C, Hummel T. A simple and reliable method for clinical assessment of odor thresholds. Chem. Senses29, 311–317 (2004).
  • Lötsch J, Reichmann H, Hummel T. Different odor tests contribute differently to the evaluation of olfactory loss. Chem. Senses33, 17–21 (2008).
  • Larsson M, Nilsson LG, Olofsson JK, Nordin S. Demographic and cognitive predictors of cued odor identification: evidence from a population-based study. Chem. Senses29, 547–554 (2004).
  • Frasnelli J, Hummel T. Olfactory dysfunction and daily life. Eur. Arch. Otolaryngol.262, 231–235 (2005).
  • Hummel T, Kobal G. Olfactory event-related potentials. In: Methods and Frontiers in Chemosensory Research. Simon SA, Nicolelis MAL (Eds). CRC Press, FL, USA 429–464 (2001).
  • Müller A, Reichmann H, Livermore A, Hummel T. Olfactory function in idiopathic Parkinson’s disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J. Neural. Transm.109, 805–811 (2002).
  • Gonera EG, Van’t Hof M, Berger HJC, Van heel CD, Horstink MWIM. Symptoms and duration of the premotor phase in Parkinson’s disease. Mov. Disord.12, 871–876 (1997).
  • Tissingh G, Berendse HW, Bergmans P et al. Loss of olfaction in de novo and treated Parkinson’s disease: possible implications for early diagnosis. Mov. Disord.16, 41–46 (2001).
  • Ponsen MM, Stoffers D, Booij J et al. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann. Neurol.56, 173–181 (2004).
  • Ponsen MM, Stoffers D, Twisk JW, Wolters ECh, Berendse HW. Hyposmia and executive dysfunction as predictors of future Parkinson’s disease: a prospective study. Mov. Disord.24(7), 1060–1065 (2009).
  • Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov. Disord.22, 839–842 (2007).
  • Sommer U, Hummel T, Cormann K et al. Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord.19(10), 1196–1202 (2004).
  • Marras C, Goldman S, Smith A. Smell identification ability in twin pairs discordant for Parkinson’s disease. Mov. Disord.20, 687–693 (2005).
  • Ross W, Petrovitch H, Abbott RD et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann. Neurol.63, 167–173 (2008).
  • Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24, 197–211 (2003).
  • Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N. Olfactory function in atypical parkinsonian syndromes. Acta Neurol. Scand.91, 247–250 (1995).
  • McKinnon JH, Demaerschalk BM, Caviness JN, Wellik KE, Adler CH, Wingerchuk DM. Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders? Neurologist13(6), 382–385 (2007).
  • Liberini P, Parola S, Spano PF, Antonini L. Olfactory dysfunction in dementia associated with Lewy bodies. Parkinsonism Relat. Disord.5, 30 (1999).
  • Williams SS, Williams J, Combrinck M, Christie S, Smith AD, McShane R. Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry80(6), 667–670 (2009).
  • Hawkes C. Olfaction in neurodegenerative disorder. Mov. Disord.18, 364–372 (2003).
  • Goldstein DS, Sewell L. Olfactory dysfunction in pure autonomic failure: implications for the pathogenesis of Lewy body diseases. Parkinsonism Relat. Disord.15(7), 516–520 (2009).
  • Katzenschlager R, Lees AJ. Olfaction and Parkinson’s syndromes: its role in differential diagnosis. Curr. Opin. Neurol.17(4), 417–423 (2004).
  • Silveira-Moriyama L, Guedes LC, Kingsbury A et al. Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data. Neurology71(13), 1021–1026 (2008).
  • Silveira-Moriyama L, Schwingenschuh P, O’Donnell A et al. Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs). J. Neurol. Neurosurg. Psychiatry80(7), 744–748 (2009).
  • Doty RL, Singh A, Tetrud J, Langston JW. Lack of major olfactory dysfunction in MPTP-induced parkinsonism. Ann. Neurol.32, 97–100 (1992).
  • Krüger S, Haehner A, Thiem C, Hummel T. Neuroleptic-induced parkinsonism is associated with olfactory dysfunction. J. Neurol.255, 1574–1579 (2008).
  • Müller A, Reuner U, Landis B, Kitzler H, Reichmann H, Hummel T. Extrapyramidal symptoms in Wilson’s disease are associated with olfactory dysfunction. Mov. Disord.21(9), 1311–1316 (2006).
  • Jankovic J. Parkinson’s disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatr.79, 368–376 (2008).
  • Hoehn MM, Yahr MD. Parkinsonism. Onset, progression and mortality. Neurology17, 427–442 (1967).
  • Berg D. Biomarkers for the early detection of Parkinson’s and Alzheimer’s disease. Neurodegener. Dis.5, 133–136 (2008).
  • Tolosa E, Gaig C, Santamaria J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology72(Suppl. 2), 12–20 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.